产品
编 号：F012559
分子式：C16H15F2N3O4S
分子量：383.37
分子式：C16H15F2N3O4S
分子量：383.37
产品类型
规格
价格
是否有货
100mg
询价
询价
500mg
询价
询价
结构图
CAS No: 102625-70-7
产品详情
生物活性：
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
体内研究：
Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin. Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats. Animal Model:Mice bearing MCF-7 or A431 xenografts
Dosage:200 mg/kg
Administration:IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
Result:Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination. Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone.
体外研究：
Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
体内研究：
Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin. Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats. Animal Model:Mice bearing MCF-7 or A431 xenografts
Dosage:200 mg/kg
Administration:IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
Result:Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination. Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone.
体外研究：
Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备